KVD900

Phase 3Small molecule

KKalVista Pharmaceuticals, Ltd.

KVD900 is one of 38 small molecule programs targeting Hereditary Angioedema. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hereditary AngioedemaRecruiting

AdolescentActive, not recruiting

Hereditary AngioedemaPhase 3

Recruiting

AdolescentPhase 3

Active, not recruiting

Competition

Competitive Landscape

30 competitors in Adolescent

#DrugCompanyPhaseTrials

Zoloft

VViatris Specialty LLC

Approved

4 2

Abilify

Otsuka

Approved

2 3

Prozac

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 3

8 4

Lithobid

SSolvay Pharmaceuticals

Phase 3

2 5

Camptosar

Pfizer

Phase 2

1 6

Cymbalta

Jazz Pharmaceuticals

Phase 2

1 7

Brintellix

Takeda

Phase 2

1 8

Sunlenca

Gilead

Phase 2

1 9

Valdoxan

Novartis

Phase 3

1 10

Zyprexa

MMODAG GmbH

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

ApprovedRecruiting

Hereditary Angioedema

NCT07654829

Clinical

Trials by Indication[1]

Hereditary Angioedema5 trials

A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

Completed·KKalVista Pharmaceuticals, Ltd.·Phase 3·NCT05259917·136 enrolled

An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

Active, not recruiting·KKalVista Pharmaceuticals, Ltd.·Phase 3·NCT05505916·145 enrolled

A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or II

Completed·KKalVista Pharmaceuticals, Ltd.·Phase 2·NCT04208412·84 enrolled

Show 2 more trials

A Phase 4, Open-Label Trial to Evaluate the Safety and Effectiveness of Sebetralstat When Used as Preprocedural Short-term Prophylaxis in Patients With Hereditary Angioedema

Recruiting·KKalVista Pharmaceuticals, Ltd.·Approved·NCT07654829·100 enrolled

Open-Label Safety, Pharmacokinetic, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With Hereditary Angioedema Type I or II

Completed·KKalVista Pharmaceuticals, Ltd.·Phase 3·NCT06467084·36 enrolled

Adolescent1 trial

PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial

Active, not recruiting·KKalVista Pharmaceuticals, Ltd.·Phase 3·NCT05511922·11 enrolled

Single Dose1 trial

A Single Dose Safety, Tolerability, Pharmacokinetic and Food Effect Study of KVD900 (Sebetralstat) in Healthy Volunteers

Completed·KKalVista Pharmaceuticals, Ltd.·Phase 1·NCT04349800·84 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for KVD900. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — KVD900 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for KVD900. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — KalVista Pharmaceuticals, Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: KKalVista Pharmaceuticals, Ltd.

KVD900

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Hereditary Angioedema5 trials

Adolescent1 trial

Single Dose1 trial

References

Drug Info

Quick Facts

Related News